左旋氨氯地平对阵发性房颤并高血压患者房颤的影响

目的观察左旋氨氯地平对阵发性房颤并高血压患者P波离散度（Pd）、左房内径、高敏C反应蛋白（hs—CRP）水平、房颤发作情况的影响。方法将阵发性房颤并高血压患者100例随机分为治疗组（50例）和对照组（50例）。降压药物治疗组给予左旋氨氯地平，对照组给予坎地沙坦，随访1年，观察治疗前后Pd、左房内径、hs—CRP水平及房颤发作情况。结果至随访结束，在长期应用胺碘酮的患者中，对照组房颤复发17例，占81．0％，治疗组房颤复发22例，占95．7％，两组之间差异无统计学意义（x^2=1．122，P〉0．05）。未长期应用胺碘酮的患者，对照组、治疗组在7-12个月时房颤发作次数均较治疗前减少（t=2．823，P〈0．01；t=2．655，P〈0．05），但两组之间差异无统计学意义（t=0．594，P〉0．05）。与治疗前比较，对照组、治疗组的Pd、左房内径、hs—CRP均降低（t=4．025-13．546，P〈0．01），治疗后两组之间Pd、左房内径、hs—CRP比较，差异无统计学意义（t=1．234-1．514，P〉0．05）。结论左旋氨氯地平可减少阵发性房颤并高血压患者房颤的复发，降低Pd、左房内径和hs—CRP水平，其效果与坎地沙坦没有差异。

Effects of levamlodipine on atrial fibrillation recurrence in paroxysmal atrial fibrillation patients with hypertension

Objective To observe the effects of levamlodipine on P wave dispersion （Pd）, left atrial di- mension, high sensitivity C-reactive protein （hs-CRP） and atrial fibrillation recurrence in paroxysmal atrial fibril- lation patients with hypertension. Methods A total of 100 paroxysmal atrial fibrillation patients with hypertension were randomly assigned to control group （n=50） or treatment group （n=50） for a 1-year follow-up. Control group were given eandesartan for hypertension, treatment group were given Levamlodipine. ACEI, other CCBs and ARBs were prohibited in all patients. Atrial fibrillation episodes, Pd, hs-CRP and left atrial dimension were observed during the follow-up. Results In the patients used amiodarone, 17 cases recurred atrial fibrillation in the control group during the follow-up, accounting for 81.0%, and 22 cases recurred atrial fibrillation in the treatment group, accounting for 95.7%. There was no difference between the two groups（X2= 1.122, P〉0.05 ）. In the patients without amJodarone application, frequency of atrial fibrillation recurrence in the 7-12 month in the control group decreased compared with pre-treatment, there were no differences of frequency in the 7-12 month between the control group and the treatment group 0=0.594, P〉0.05）. After 1 year treatment, all of Pd, left atrial dimension and hs-CRP decreased both in the control group and the treatment group（t=4.025-13.546, P〈0.01 ）. There were no differences of Pd, left atrial dimension and hs-CRP between the control group and the treatment group （t=1.234-1.514, P〉 0.05 ）. Conclusion In patients with paroxysmal atrial fibrillation and hypertension, levamlodipine can reduce the atrial fibrillation recurrence, decrease Pd, hs-CRP and left atrial dimension. Its effects on paroxysmal atrial fibril- lation are similar to candesartan.